SyntheticMR’s quantitative imaging software solution, SyMRI 12, has been granted regulatory approval by the Taiwan Food and Drug Administration (TFDA).
This authorisation facilitates the introduction of SyMRI 12 to the Taiwanese market, marking a significant stride in SyntheticMR’s strategy for regional expansion.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
SyntheticMR CEO Ulrik Harrysson expressed enthusiasm about the new development, stating: “This approval of SyMRI 12 opens new opportunities for us to expand our market presence in Taiwan and the Southeast Asia region. We are excited to offer SyMRI 12 to radiologists in this market, providing them with new insights and enhancing their practice through our unique technology and objective, quantitative data.”
SyntheticMR stated that the TFDA’s approval marks a significant step in enhancing healthcare in Taiwan through advanced imaging technology.
The company’s entry into the Taiwanese market is anticipated to foster improvements in patient care outcomes and bolster its presence in the Asia-Pacific region.
SyMRI 12 is engineered to provide a comprehensive suite of contrast-weighted images and quantitative data from a single rapid scan, which can significantly optimise imaging workflows and support objective decision-making in clinical practices.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSyntheticMR’s innovative software solutions are claimed to refine clinical decisions, streamline operations, and elevate patient care.
SyntheticMR offers magnetic resonance imaging (MRI) software solutions. Its flagship product, SyMRI, generates adjustable contrast images and quantitative data from a mere five-minute scan. The solution is available in various configurations to cater to different medical needs.
SyMRI NEURO, one of the packages offered, delivers detailed brain imaging, tissue segmentation, and quantitative analysis. In June, SyntheticMR announced the CE marking of SyMRI NEURO version 15, its advanced imaging solution.
SyMRI MSK, another variant, provides imaging and data for knee and spine anatomies. Both SyMRI NEURO and SyMRI MSK have received CE marking, with SyMRI NEURO also cleared by the FDA under the 510(k) provision. Meanwhile, SyMRI 3D is pending 510(k) clearance and has been CE-marked. SyMRI is a registered trademark in both Europe and the US.
